![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine is being investigated for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: MELT-300
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2024
Details:
The funding is intended to support the clinical advancement of MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine. This medication is designed for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: MELT-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 02, 2024
Details:
Under the agreement, Melt Pharmaceuticals will utilize Catalent’s proprietary Zydis® orally disintegrating tablet fast-dissolve technology with MELT-300 (midazolam), a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Melt-300
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 26, 2023
Details:
MELT-300 combines fixed doses of midazolam (3mg) and ketamine (50mg) in one rapidly dissolving tablet (RDT) that is administered sublingually for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: MELT-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
MELT-300 combines fixed doses of midazolam (3mg) and ketamine (50mg) in one dissolvable tablet that is administered sublingually for procedural sedation and analgesia during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: MELT-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
MELT-210 is a fixed dose of 3 mg of midazolam formulated in a proprietary rapidly dissolving sublingual tablet using its proprietary Zydis® orally disintegrating tablet (ODT) technology to create a tablet that dissolves quickly when placed under the tongue.
Lead Product(s): Ketamine Hydrochloride,Midazolam
Therapeutic Area: Neurology Product Name: MELT-210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
Melt Pharmaceuticals will use the proceeds to conduct Phase 2 efficacy study for the lead drug candidate, MELT-300, a combination of midazolam and ketamine in a rapidly dissolving, sublingual tablet to provide sedation and analgesia for patients undergoing cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: MELT-300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harrow Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 02, 2021
Details:
MELT is a patented combination of midazolam and ketamine in a rapidly dissolving, sublingual tablet to provide sedation and analgesia for patients undergoing cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021
Details:
MELT-100 is a patented combination of midazolam and ketamine in a rapidly dissolving, sublingual tablet to provide sedation and analgesia for patients undergoing cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: MELT-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020